Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms POLYP 1
  • Sponsors Roche

    • Most Recent Events

    • 09 Nov 2023 Results of pooled post hoc analysis POLYP 1 and POLYP 2 and the open-label extension (OLE) trials assessing impact of the allergic and asthma status on omalizumab treatment in patients with CRSwNP published in the Annals of Allergy, Asthma and Immunology
    • 18 May 2022 Results of (SYNAPSE [mepolizumab], SINUS 24/52 [dupilumab], POLYP 1/2 [omalizumab]) assessing the feasibility of conducting an ITC to obtain unbiased estimates of the relative efficacy of biologics for treatment of uncontrolled chronic rhinosinusitis with nasal polyps, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 08 Nov 2021 Results of a s post hoc analysis assessed subgroups from the OLE study of the POLYP 1 (NCT03280550) and 2 (NCT03280537) to compare the efficacy of omalizumab in patients with nasal polyps with or without physician-reported allergic comorbidities presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top